Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceutical Chemicals

Specialty ingredient firm Aceto relaunches as Actylis

by Michael McCoy
October 1, 2022 | A version of this story appeared in Volume 100, Issue 35

 

After making 10 acquisitions, the specialty ingredient company Aceto has relaunched as Actylis. The buying spree happened under the leadership of CEO Gilles Cottier, who joined the firm in 2019, after it was acquired by New Mountain Capital. At a press conference, Cottier said Actylis has grown since then, from 200 employees to 850. The company expects to spend $25 million this year to expand its capabilities, including at the former Cascade Chemistry in Eugene, Oregon. Actylis has completed a second facility there to make drug intermediates and active ingredients.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.